Cognitive Impairment in Major Depressive Disorder
Clinical Relevance, Biological Substrates, and Treatment Opportunities

Major depressive disorder (MDD) is the leading cause of disability globally in both developed and developing nations. The staggering economic costs attributable to MDD are largely a consequence of impairment in role function. Evidence indicates that disturbance in the domain of cognitive function in individuals with MDD is the principal determinant of health outcome. This is the first book to comprehensively explore the domain of cognition in MDD. The literature describing cognitive dysfunction is reviewed with particular focus on clinical determinants, pathophysiology and causative factors. The patient subpopulations most susceptible are defined. A summary of contemporary assessment tools for research and clinical purposes is provided. Multimodality treatments and prevention strategies are described. This book is an invaluable resource for psychiatrists, neuropsychologists and other members of the mental health team, as well as for policy makers, vocation rehabilitation experts, disability providers and other stakeholders interested in improving health outcomes in MDD.

Preface; Part I. Clinical Relevance of Cognitive Dysfunction in Major Depressive Disorder: 1. Does cognitive dysfunction predate the onset of incident depression? Julia Buthmann, Danielle S. Cha and Roger S. McIntyre; 2. Understanding the importance of cognitive dysfunction and cognitive change in major depressive disorder Paul Maruff and Judith Jaeger; 3. Cognition in MDD implications for primary care Larry Culpepper; 4. Neurocognition in pediatric depression Dwight Newton, Melanie Naiberg and Benjamin Goldstein; 5. Neuroanatomy of cognition in major depressive disorder (hot and cold) Guy M. Goodwin; 6. Hot and cold cognition in major depressive disorder Oliver Robinson, Jonathan Rosier and Barbara Sahakian; 7. Social cognition and emotional processing in major depressive disorder Philippe Fossati and Sophie Hinfray; 8. The role of social cognition in major depressive disorder Bernhard Baune and Michael Weightman; 9. Are cognitive deficits in major depressive disorder progressive? Philip Gorwood and Marie Laure Clery-Melin; 10. Implications of cognitive impairments on functional outcomes in major depressive disorder Tracy L. Greer and Cassandra R. Hatt; Part II. Underlying Biological Substrates Associated with Cognitive Dysfunction in Major Depressive Disorder: 11. Cognition and biomarkers in major depressive disorder (MDD): endophenotype or epiphenomenon? Shane McInerney, Philip Gorwood and Sidney Kennedy; 12. Inflammation and cognition in major depressive disorder Bernhard Baune; 13. HPA axis and cognitive dysfunction in mood disorders Rebecca Strawbridge and Allan H. Young; 14. White matter neurobiology and cognitive dysfunction in major depressive disorder Geoffrey Chern-Yee Tan and Kang Sim; 15. Insulin resistance and implications for hippocampal volume/function the default mode network Heather A. Kenna, Tonita E. Wroolie, Danielle R. Balzafiore and Natalie L. Rasgon; Part III. Evaluating Cognitive Dysfunction in Major Depressive Disorder: 16. Measuring the mind: detecting cognitive deficits and measuring cognitive change in patients with depression John Harrison; 17. Subjective measures of cognitive dysfunction in major depressive disorder Raymond Lam; Part IV. Treatment Opportunities for Ameliorating Cognitive Dysfunction in Major Depressive Disorder: 18. Neuroscience of functional outcomes and treatment targets in major depressive disorder Lisanne M. Jenkins, Amy Peters, Rachel H. Jacobs and Scott A. Langenecker; 19. Treatment of cognitive dysfunction in adults with major depressive disorder Roger S. McIntyre, Kahlood Syeda and Danielle S. Cha; 20. A novel treatment targeting cognitive dysfunction in mood disorders Kamilla W. Miskowiak; 21. Cognitive remediation for major depressive disorder Christopher Bowie; 22. Exercise and cognition Guy Faulkner, Mark Duncan and Mehala Subramaniapillai; Index.

Roger S. McIntyre is Head of the Mood Disorders Psychopharmacology Unit, University Health Network, and Professor of Psychiatry and Pharmacology, University of Toronto, ON, Canada.